The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler

Respiratory Medicine

Volumn 97, Issue SUPPL. D, 2003, Pages

  Ganderton, D ^a   Lewis, D ^a   Davies, R ^a   Meakin, B ^a   Church, T ^a  

^a VECTURA GROUP PLC   (United Kingdom)

Author keywords

Aerosol; Budesonide; CFC; Hydrofluoroalkane HFA; Particle size distribution; pMDI

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE MODULITE; CHLOROFLUOROCARBON; CORTICOSTEROID; DESONAC DA; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL SULFATE; SORBITAN TRIOLEATE;

AEROSOL; ARTICLE; ASTHMA; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PREFERENCE; DRY POWDER; EVALUATION; HUMAN; IN VITRO STUDY; METERED DOSE INHALER; OROPHARYNX; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0346758138     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.10.003     Document Type: Article

References (13)

1. Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurised metered dose inhaler P-MDI. Eur Resp J 1994; 7:1839-44.
2. Ball DJ, Hirst PH, Newman SP. et al. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder inhaler. Int J Pharm 2002; 245:123-32.
3. Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and a pMDI plus spacer in asthmatic patients. Respir Med 2001;95:720-7.
4. Frew AJ, Langley SJ, Perrin V, et al. Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel Inhaler Airmax® and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patient with mild asthma. Respir Med 2002;96:542-7.
5. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic airways disease: a systematic review of the literature. Health Technol Assess 2001;5:1-149.
6. Tansey I. Technological development of Airomir® (salbutamol sulphate in CFC-free system) MDI. Br J Clin Prac 1995;79(Suppl):13-5.
7. Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94(Suppl B):S3-9.
8. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug disposition in humans. J Allergy Clin Immunol 1999;104:S250-2.
9. Tashkin DP. Extra-fine corticosteroid aerosols for hydrofluoroalkane-134a metered dose inhalers. Advantages and disadvantages. Chest 1999;115:316-8.
10. Ganderton D, Lewis D, Davies R, et al. Modulite®: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002;96(Suppl D):S3-8.
11. Acerbi D, Deroubaix X, DeBruyn S, et al. Biopharmaceutical optimisation of a new CFC-free budesonide pMDI. Respir Drug Deliv VIII 2002:391-3.
12. Poli G. Acerbi D, Simonon A, et al. Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation. European Respiratory Society Annual Congress 2001 (ERS 2001), Berlin, September 22-26, 2001.
13. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurised metered-dose inhaler attached to a spacer. Eur Respir J 1998;12:1340-5.